Infections and fingolimod;Infecciones y fingolimod

Revista de Neurologia

Volumn 55, Issue 4, 2012, Pages 227-237

  Cervera, Carlos ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Fingolimod; Lymphopenia; Multiple sclerosis; Opportunistic infection; Prevention; Progressive multifocal leuko encephalopathy; Vaccination

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

DISEASE SEVERITY; DRUG MECHANISM; EFFECTOR CELL; HERPES SIMPLEX; HUMAN; IMMUNOSURVEILLANCE; INFECTION; INFECTION RISK; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; T LYMPHOCYTE;

EID: 84865228134     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5504.2012164     Document Type: Review

References (74)

1. Cohen JA, Barkhof F, Comi G, Hartung H P, Khatri BO, Montalban X, et al. Oral fngolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
2. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
3. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
4. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. Te immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
5. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafcking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
6. Oo ML, Tangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007; 282: 9082-9089.
7. Cohen JA, Chun J. Mechanisms of fngolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011; 69: 759-777.
8. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
9. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279: 15396-15401.
10. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
12. Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into infamed tissues. Nature 1997; 385: 81-83.
13. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54-60.
14. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
15. García-Merino J, Sánchez A. Mecanismos básicos de acción del fngolimod en relación con la esclerosis múltiple. Rev Neurol 2012; 55: 31-37.
16. Quesniaux V, Fullard L, Arendse H, Davison G, Markgraaf N, Auer R, et al. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immuno-suppression in baboons. Transpl Immunol 1999; 7: 149-157.
17. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108: 45-51.
18. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999; 17: 625-656.
19. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
20. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 2001; 410: 974-979.
21. Michael NL. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999; 11: 466-474.
22. Mireille L, Anna S, Marie-Christine C, Valerie M, Bruno H, Jerome E. Death of effector memory T cells characterizes AIDS. Front Biosci 2009; 14: 4386-4400.
23. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ter 2001; 1: 1059-1065.
24. van der Windt DJ, Smetanka C, Macedo C, He J, Lakomy R, Bottino R, et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010; 10: 773-783.
25. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, et al. FTY720 therapy exerts diferential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267.
26. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004; 44: 532-537.
27. Walsh KB, Marsolais D, Welch MJ, Rosen H, Oldstone MB. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 2010; 397: 260-269.
28. Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011; 69: 408-413.
29. Francis G, Kappos L, O'Connor P, Collins W, Zhang-Auberson L, De Vera A, et al. Lymphocytes and fingolimod -temporal pattern and relationship with infections. Mult Scler 2010; 16 (Suppl 10): S41-S196.
30. Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007; 84: 885-892.
31. Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant 2011; 26: 3802-3805.
32. Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Méndez R, Carvalho DB, et al. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clin Transplant 2009; 23: 589-599.
33. Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012; 8: 143-151.
34. De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159: 51-53.
35. Salvetti M, Pisani A, Bastianello S, Milleforini E, Buttinelli C, Pozzilli C. Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. J Neurol 1995; 242: 143-146.
36. Farez MF, Ysrraelit MC, Fiol M, Correale J. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult Scler 2012; 18: 254-256.
37. Cilla G, Montes M, Artieda J, Piñeiro L, Arriola L, Pérez-Trallero E. Measles genotypes D4 and G3 reintroduced by multiple foci after 15 years without measles virus circulation, Gipuzkoa, the Basque Country, Spain, March to June 2011. Euro Surveill 2011; 16: 19997.
38. Martínez-Romero M, Martínez-Diz S, García-Iglesias F. Why don't parents vaccinate their children? Reffections on a measles outbreak in a neighborhood of Granada. An Pediatr (Barc) 2011; 75: 209-210.
39. López-Hernández B, Laguna-Sorinas J, Marín-Rodríguez I, Gallardo-García V, Pérez-Morilla E, Mayoral-Cortés JM. Spotlight on measles 2010: an ongoing outbreak of measles in an unvaccinated population in Granada, Spain, October to November 2010: an ongoing outbreak of measles in an unvaccinated population in Granada, Spain, October to November 2010. Euro Surveill 2010; 15: 19746.
40. Nieto-Vera J, Rodríguez-Benjumeda LM, Mosquera-Gutiérrez MM, Mayoral-Cortés JM, Masa-Calles J. Measles outbreak in Campo de Gibraltar, Cadiz, Spain, during the period February-July 2008. Rev Esp Salud Publica 2010; 84: 203-214.
41. Sanz-Moreno JC, García-Comas L, Ramírez-Fernández R, Ramos-Blázquez B, Ordobas-Gavín M. Evolution of measles, rubella and mumps from the third seroepidemiological survey in the autonomous region of Madrid, Spain. Rev Esp Salud Publica 2009; 83: 625-637.
42. Monfort L, Muñoz D, Trenchs V, Hernández S, García JJ, Aguilar AC, et al. Measles outbreak in Barcelona. Clinical and epidemiological characteristics. Enferm Infecc Microbiol Clin 2010; 28: 82-86.
43. Domínguez A, Torner N, Barrabeig I, Rovira A, Rius C, Cayla J, et al. Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule. Clin Infect Dis 2008; 47: 1143-1149.
44. Nieto-Vera J, Masa-Calles J, Dávila J, Molina-Font J, Jiménez M, Gallardo-García V, et al. An outbreak of measles in Algeciras, Spain, 2008 -a preliminary report. Euro Surveill 2008; 13: 18872.
45. García-Comas L. Measles outbreak in the region of Madrid, Spain, 2006. Euro Surveill 2006; 11: e060330.
46. Peña-Rey I, Martínez de Aragón V, Mosquera M, De Ory F, Echevarría JE. Measles risk groups in Spain: implications for the European measles-elimination target. Vaccine 2009; 27: 3927-3934.
47. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-1206.
48. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-509.
49. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319-326.
50. González-Martín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R, et al. Consensus document on the diagnosis, treatment and prevention of tuberculosis. Enferm Infecc Microbiol Clin 2010; 28: 297.e1-e20.
51. Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006; 6: 1902-1910.
52. Connor LM, Harvie MC, Rich FJ, Quinn KM, Brinkmann V, Le Gros G, et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol 2010; 40: 2482-2492.
53. Aström KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81: 93-111.
54. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1: 66. 1257-1260.
55. White MK, Safak M, Khalili K. Regulation of gene expression in primate polyomaviruses. J Virol 2009; 83: 10846-10856.
56. Walker DL, Padgett BL. Te epidemiology of human polyomaviruses. Prog Clin Biol Res 1983; 105: 99-106.
57. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus 68. SV40. J Med Virol 2003; 71: 115-123.
58. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5: e1000363.
59. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009;70. 199: 837-846.
60. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence 71. for site of initial viral infection. J Virol 1998; 72: 9918-9923.
61. Kato A, Kitamura T, Takasaka T, Tominaga T, Ishikawa A, Zheng HY, et al. Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol 2004; 10: 244-249.
62. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy -revisited. J Infect Dis 2011; 203: 578-586.
63. Brew BJ, Davies NW, Cinque P, Cliford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010; 6: 667-679.
64. Jensen PN, Major EO. Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. J Leukoc Biol 1999; 65: 428-438.
65. Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. Virology 1994; 198: 59-70.
66. Gallia GL, Houf SA, Major EO, Khalili K. Review: JC virus infection of lymphocytes -revisited. J Infect Dis 1997; 176: 1603-1609.
67. Wuthrich C, Kesari S, Kim WK, Williams K, Gelman R, Elmeric D, et al. Characterization of lymphocytic infltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(+) T cells with JCV-infected glial cells. J Neurovirol 2006; 12: 116-128.
68. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 2011; 204: 237-244.
69. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361: 1067-1074.
70. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350-1354.
71. Morris MA, Gibb DR, Picard F, Brinkmann V, Straume M, Ley K. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur J Immunol 2005; 35: 3570-3580.
72. Vennegoor A, Wattjes MP, Van Munster ET, Kriekaart RL, Van Oosten BW, Barkhof F, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011; 76: 574-576.
73. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381.
74. Cliford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.